EXPOSED: One in Seven Vaccinated People Report Serious Adverse Events — And the Cover-Up Continues

Key Takeaways

• MHRA active surveillance found 13.7% serious adverse events among 30k participants
• Cohort includes 35.6% pre‑vaccination, 47.5% post‑vaccination, 16.9% unclassified
• No stratified analysis published to assess reporting bias
• Dropout after first dose left under half reporting later doses
• Pregnancy and menstrual safety data were incomplete, limiting conclusions

Pulse Analysis

Active surveillance systems like the MHRA’s Yellow Card Vaccine Monitoring (YCVM) were designed to overcome the under‑reporting inherent in passive schemes. By recruiting participants and prompting regular updates, regulators hoped to capture a more accurate picture of COVID‑19 vaccine safety. The recent release of the YCVM dataset, however, reveals that the promised methodological rigor was undermined by delayed publication and a lack of critical subgroup analysis, leaving stakeholders without a clear signal of true risk.

The most striking omission is the failure to separate pre‑vaccination enrolments from post‑vaccination sign‑ups, a step essential for quantifying reporting bias. Without this stratification, the 13.7% rate of medically serious events could be inflated by individuals who joined the study after experiencing an adverse reaction. Compounding the issue, more than half of the original cohort stopped reporting after the first dose, obscuring trends across subsequent doses. Pregnancy outcomes and menstrual disturbances were also reported without sufficient follow‑up, preventing definitive safety conclusions for these sensitive subpopulations.

For regulators, the episode underscores the need for transparent, timely analysis of active‑surveillance data. Policymakers and the public rely on clear risk assessments to maintain confidence in vaccination programs. Moving forward, the MHRA and other agencies must publish stratified results, address dropout biases, and link cohort data to national health records. Only with rigorous, open reporting can the true benefit‑risk balance of COVID‑19 vaccines be accurately communicated and future surveillance efforts be trusted.